In the News

FDA’s Shift From Animal Testing Opens Doors for Organoid Makers

April 30, 2025
Loading the Elevenlabs Text to Speech AudioNative Player...
The idea that a mouse brain or a rat brain or any other animal brain can predict how a human brain would react to a particular drug—it's not credible. Yet up until this point, this has been the only solution that pharma has had available to them.

-

‍

Related Stories

Spotlight
2/5/2026
Organoid Neurotoxicity Testing Embraced by FDA and NIH
Scientists and regulators have long acknowledged the weaknesses in traditional methods used to identify drugs that may harm the central nervous system.
In the News
7/17/2023
AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets
AxoSim has entered a definitive agreement to acquire Vyant Bio's StemoniX microBrain™ platform, uniting top-tier organoid technologies to accelerate neurological drug discovery.
In the News
2/28/2024
AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors
Serial entrepreneurs Dale Pfost and David Weiner bring broad expertise as AxoSim expands its leadership in human organoid technologies designed to make neurological R&D faster, more efficient and more successful.
Join our mailing list.
Thank you! Your submission has been received.
Something went wrong while submitting the form.
© 2025 28bio. All rights reserved.
Privacy Policy
Terms of Use
FCOI Polcy